Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001).
M. Ueno
No relevant relationships to disclose
S. Ohkawa
No relevant relationships to disclose
K. Sugimori
No relevant relationships to disclose
S. Kobayashi
No relevant relationships to disclose
T. Kaneko
No relevant relationships to disclose
M. Taguri
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose